The hemophilia treatment market is entering a pivotal decade, shaped by novel non-factor drugs, gene therapy breakthroughs, and a steadily expanding diagnosed patient base. Within the broader hemophilia market, the hemophilia A segment commands the largest share, reflecting both its higher global prevalence and the intensity of R&D activity aimed at correcting factor VIII deficiency.

Hemophilia A Market Size and Forecast

The hemophilia A market size stood at USD 12,918 million in 2025 across the 7MM (US, EU4, UK, and Japan) and is expected to climb to USD 16,756 million by 2034, advancing at a CAGR of 2.9%. The US alone contributed close to USD 5,920 million in 2024, making it the single largest country market, while EU4 and the UK combined accounted for roughly 58% of the 7MM diagnosed prevalent population. Japan's hemophilia A treatment market was valued near USD 1,150 million in 2024. This upward trajectory in the hemophilia market size is being fueled by rising diagnosis rates alongside premium-priced, longer-acting, and curative-intent therapies entering the market.

Hemophilia Epidemiology and Patient Burden

Turning to hemophilia A epidemiology, the 7MM diagnosed prevalent pool numbered close to 49,500 cases in 2024, with a modest rise to around 50,000 projected by 2034 — a trend captured in the latest hemophilia A epidemiology forecast. Broader hemophilia epidemiology analysis segments patients by severity: in the US, about 35% of cases are mild, 15% moderate, and 50% severe, while roughly 2,000 US patients carry inhibitors against 12,700 without. A related but separate condition, hemophilia B, caused by factor IX deficiency rather than factor VIII, shares several treatment pathways with hemophilia A, and the hemophilia B market is similarly benefiting from newer non-factor therapies approved for dual indications.

Hemophilia A Drugs and Treatment Landscape

For decades, hemophilia A treatment relied on factor VIII replacement — first through plasma-derived concentrates and later through recombinant technology. Today's recombinant factor VIII market features products such as ADVATE, ELOCTATE, KOGENATE FS, JIVI, and ALTUVIIIO, while hemophilia A drugs derived from human plasma, like HEMOFIL-M and MONOCLATE-P, retain a smaller niche. HEMLIBRA has emerged as a preferred prophylactic choice for patients with inhibitors. More recently, the hemophilia drugs market has diversified beyond factor concentrates: Pfizer's HYMPAVZI (anti-TFPI, approved October 2024) and Sanofi's QFITLIA (an antithrombin-lowering siRNA therapy approved March 2025) now serve patients aged 12 and older, regardless of inhibitor status, broadening the overall hemophilia treatment drugs market.

A distinct clinical scenario, acquired hemophilia A, arises when the body generates antibodies against its own factor VIII. OBIZUR (susoctocog alfa) is purpose-built for this population, representing a small but critical niche within the acquired hemophilia A treatment market.

Gene Therapy: Reshaping Hemophilia A Treatment

Gene therapy is arguably the most disruptive force in the hemophilia gene therapy market. BioMarin's ROCTAVIAN, an AAV5-based one-time infusion, received FDA approval in June 2023 for adults with severe hemophilia A, aiming to enable durable, endogenous factor VIII production. Elsewhere in the hemophilia A gene therapy space, Pfizer's giroctocogene fitelparvovec posted strong Phase III data in July 2024, with 84% of trial participants sustaining FVIII activity above 5% at 15 months, reinforcing gene therapy's role in the evolving factor VIII deficiency treatment paradigm.

Pipeline Momentum and Market Outlook

The hemophilia A pipeline remains crowded and competitive. Novo Nordisk (Mim8/denecimig, ALHEMO), Roche/Chugai (NXT007), Sangamo Therapeutics, ASC Therapeutics (ASC-618), and Ultragenyx (DTX201) are all advancing candidates through Phase I–III trials. Mim8, a bispecific antibody offering once-weekly or once-monthly subcutaneous dosing, is among the furthest along and could reshape treatment convenience for patients with and without inhibitors.

Regional Spotlight: The US and the Wider Bleeding Disorders Market

The US hemophilia treatment market continues to set the pace globally, benefiting from early drug launches, strong reimbursement infrastructure, and the largest diagnosed patient pool among the 7MM. Zooming out, the bleeding disorders treatment market — spanning hemophilia A, hemophilia B, and rarer clotting factor deficiencies — is being reshaped in parallel by RNAi platforms, bispecific antibodies, and gene therapy. As factor VIII deficiency management continues to mature, the direction is clear: fewer infusions, better safety, and treatment options that work independent of inhibitor status, pointing toward a markedly improved standard of care for the hemophilia community.

Latest Reports Offered by Delveinsight

novel drug delivery devices market | nrg fusion market | ocular motility disturbance market | opioid related disorders market | opioid use disorder market | opioid-related disorders market | optic atropy market | optic neuritis market | orthopedic splints device market | osteoarthritis market | osteomyelitis market | paroxysmal nocturnal hemoglobinuria market | partial seizure market | pd/l-1 market | pd/pdl-1 inhibitors market | pde4 inhibitor market | pediatric brain tumor market | pediatric obesity market | pelvic organ prolapse market | percutaneous mechanical circulatory support market | pericarditis market | peripheral vascular devices market market | perivascular epithelioid cell tumor market | persistent depressive disorder market | persistent epithelial defect market | persistent epithelial defects market | pertussis market | pheochromocytomas and paragangliomas market | 

About Delveinsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com